Business
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patient
About this update from Pyxis Oncology, Inc.
[{"type":"image","alt":"Pyxis Oncology","displaySize":"","headline":null,"caption":"Pyxis Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":203,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IX0t534d6HFsYbdc2gj8WA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c","width":203,"height":105}},"lazy":false},{"type":"text","content":"- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death","length":246,"tagName":"p"},{"type":"text","content":"- On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026","length":343,"tagName":"p"},{"type":"text","content":"- On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting multiple tumor types including 1L/2L HNSCC patients in second half of 2025","length":189,"tagName":"p"},{"type":"text","content":"- Expected cash runway through data milestones and into second half of 2026","length":80,"tagName":"p"},{"type":"text","content":"BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2025, and provided a business update.","length":281,"tagName":"p"},{"type":"text","content":"“We are enthusiastic about the progress we are making with micvotabart pelidotin, particularly our recent preclinical data that validate its unique three-pronged mechanism of action and indicate that MICVO monotherapy may be eliciting immune responses in previously unresponsive tumors,” said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology. “Our focus remains on delivering du...